Skip to main content

Table 1 Patient demographics

From: Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan

 

Type 1 GD (N = 8)

Type 2 GD (N = 11)

Type 3 GD (N = 11)

Total (N = 30)

Sex, n (%)

    

 Male

5 (62.5)

6 (54.5)

6 (54.5)

17 (56.7)

 Female

3 (37.5)

5 (45.5)

5 (45.5)

13 (43.3)

Age, years, mean (SD)

53.5 (12.6)

3.4 (3.8)

20.1 (4.7)

22.9 (21.4)

Treatment status, n (%)

    

 Naïve

3 (37.5)

3 (27.3)

1 (9.1)

7 (23.3)

 Experienced

5 (62.5)

8 (72.7)

10 (90.9)

23 (76.7)

  1. Basic demographics data including sex, age and treatment status are displayed for patients with Type 1, 2 and 3 GD
  2. GD Gaucher disease, SD standard deviation